 |
 |
 |
 |
 |
 |
|
|||
 |
 |
 |
|||||||
|
||||||||||||||||
|
||||||||||||||||
The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. REFERENCESAPA (American Psychiatric Association). 1994. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: APA. APA. 2000. Diagnostic and Statistical Manual of Mental Disorders; Text Revision. 4th ed. Washington, DC: APA. Arvai JL. 2003. Using risk communication to disclose the outcome of a participatory decisionmaking process: effects on the perceived acceptability of risk-policy decisions. Risk Anal 23(2):281-9. Ball LK, Ball R, Pratt RD. 2001. An assessment of thimerosal use in childhood vaccines. Pediatrics 107(5):1147-54. Bernard S, Enayati A, Redwood L, Roger H, Binstock T. 2001. Autism: a novel form of mercury poisoning. Med Hypotheses 56(4):462-71. Blaxill M. 2001. Presentation to the Immunization Safety Review Committee. Rising Incidence of Autism: Association with Thimerosal. Cambridge, MA. Bradstreet J. 2004. Presentation to the Immunization Safety Review Committee. Biological Evidence of Significant Vaccine Related Side-effects Resulting in Neurodevelopmental Disorders. Washington, DC. CDC (Centers for Disease Control and Prevention). 1999. Thimerosal in vaccines: a joint statement of the American Academy of Pediatrics and the Public Health Service. Morb Mortal Wkly Rep 48(26):563-5. Dales L, Hammer SJ, Smith N. 2001. Time trends in autism and in MMR immunization coverage in California. JAMA 285(9):1183-5. DeStefano F, Bhasin TK, Thompson WW, Yeargin-Allsopp M, Boyle C. 2004. Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study in metropolitan Atlanta. Pediatrics 113(2):259-66. DeWilde S, Carey IM, Richards N, Hilton SR, Cook DG. 2001. Do children who become autistic consult more often after MMR vaccination? British J General Practice 51(464):226-7. Farrington CP, Miller E, Taylor B. 2001. MMR and autism: further evidence against a causal association. Vaccine 19(27):3632-5. FDA (Food and Drug Administration). 2001. Thimerosal content in some currently manufactured U.S. Licensed vaccines (table). [Online] Available: URL http://www.fda.gov/cber/vaccine/thimcnt.htm [accessed July, 2001]. FDA. 2004. Thimerosal content in vaccines. (Email communication from Karen Midthun, Food and Drug Administration, May 7, 2004). Filipek PA, Accardo PJ, Baranek GT, Cook EH, Dawson G, Gordon B, Gravel JS, Johnson CP, Kallen RJ, Levy SE, Minshew NJ, Ozonoff S, Prizant BM, Rapin I, Rogers SJ, Stone WL, Teplin S, Tuchman RF, Volkmar FR. 1999. The screening and diagnosis of autistic spectrum disorders. J Autism Dev Disord 29(6):439-84. Fombonne E. 1999. The epidemiology of autism: a review. Psychol Med 29(4):769-86. Fombonne E, Chakrabarti S. 2001. No evidence for a new variant of measles-mumps-rubella-induced autism. Pediatrics 108(4):E58. Fombonne E. 2003. The prevalence of autism. JAMA 289(1):87-9. Geier DA, Geier MR. 2003a. An assessment of the impact of thimerosal on childhood neurodevelopmental disorders. Pediatr Rehabil 6(2):97-102. Geier M, Geier D. 2003b. Neurodevelopmental disorders after thimerosal-containing vaccines: a brief communication. Exp Biol Med (Maywood) 228(6):660-4. Geier M, Geier D. 2003c. Pediatric MMR vaccination safety. International Pediatrics 18(2):203-8. Geier MR, Geier DA. 2003d. Thimerosal in childhood vaccines, neurodevelopmental disorders, and heart disease in the United States. J Amer Phys Sur 8(1):6-11.
|
|
|||||||||||||||
